Nanobiotix: Review of the first quarter of 2026

Nanobiotix, a biotechnology company specializing in innovative cancer treatments, announced an €86.1 million capital increase in May 2026, bolstering its cash reserves to accelerate its research. As of March 31, 2026, the company had €42.1 million in cash, sufficient until 2029 according to its forecasts.

Significant progress has been made in clinical trials, particularly with the JNJ-1900 (NBTXR3) treatment. Results presented at ESTRO 2026 show promising efficacy in patients with inoperable stage 3 non-small cell lung cancer. The FDA has also approved modifications to the pivotal NANORAY-312 study, allowing for a faster conclusion.

Nanobiotix continues the development of its nanotech platform with encouraging new results presented at the AACR 2026 meeting. These advances demonstrate significant potential for future therapies.